InnoCare Pharma Limited (9969.HK)
- Previous Close
9.670 - Open
9.660 - Bid 9.910 x --
- Ask 9.920 x --
- Day's Range
9.600 - 10.080 - 52 Week Range
4.220 - 10.960 - Volume
6,860,000 - Avg. Volume
13,894,086 - Market Cap (intraday)
20.873B - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.280 - Earnings Date May 13, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.71
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, the company develops ICP-189 and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, the company offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. The company has a clinical collaboration with ArriVent Biopharma, Inc. to evaluate the anti-tumor activity and safety of ICP-189 combined with furmonertinib in patients with advanced non-small cell lung cancer. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
www.innocarepharma.comRecent News: 9969.HK
View MorePerformance Overview: 9969.HK
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9969.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9969.HK
View MoreValuation Measures
Market Cap
20.87B
Enterprise Value
14.36B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.35
Price/Book (mrq)
2.40
Enterprise Value/Revenue
13.14
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-43.65%
Return on Assets (ttm)
-3.52%
Return on Equity (ttm)
-6.50%
Revenue (ttm)
1.01B
Net Income Avi to Common (ttm)
-440.63M
Diluted EPS (ttm)
-0.280
Balance Sheet and Cash Flow
Total Cash (mrq)
7B
Total Debt/Equity (mrq)
23.34%
Levered Free Cash Flow (ttm)
-664.21M